Federal grants to Eydis Bio, Inc.
Eydis Bio, Inc. in Durham, North Carolina received $5.9 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Cardiovascular Diseases Research, with $3.2 million. In fiscal 2025 it was awarded $1.4 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$5.9 million
- Awards5
- Awarded in FY 2025$1.4 million
- Largest award$2.6 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $1.6 million |
| FY 2022 | 2 | $1.2 million |
| FY 2023 | 0 | $0 |
| FY 2024 | 2 | $1.7 million |
| FY 2025 | 1 | $1.4 million |
Programs that fund Eydis Bio, Inc.
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 2 | $3.2 million |
| Arthritis, Musculoskeletal and Skin Diseases Research | 1 | $1.7 million |
| Aging Research | 1 | $506,267 |
| Drug Use and Addiction Research Programs | 1 | $480,955 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $5.9 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease - project summary / abstract systemic sclerosis interstitial lung disease (ssc-ild) is a progressive orphan disease highlighted by pulmonary fibrosis leading to a high mortality rate. Currently, there are on | Cardiovascular Diseases Research | July 10, 2024 | $2.6 million |
| Preclinical development of the TAK1 inhibitor HS-276 for the treatment of rheumatoid arthritis - project summary / abstract rheumatoid arthritis (RA) is a chronic inflammatory disease in which hyperactivated immune cells induce maladaptive persistent inflammation in the joints, leading to synovial i | Arthritis, Musculoskeletal and Skin Diseases Research | September 22, 2021 | $1.7 million |
| Acute inhibition of TAK1 as a means to control COVID-19 pulmonary hyperinflammation - project summary/abstract the recent pandemic of novel coronavirus, COVID-19, has had a devastating effect on the health and well-being of individuals across the globe, including over 3.1 million confirmed infected | Cardiovascular Diseases Research | July 29, 2021 | $593,995 |
| Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for alzheimer's disease - project summary / abstract the phase i sttr grant proposal aims to address the escalating global health challenge posed by alzheimer's disease (AD) by t | Aging Research | September 12, 2024 | $506,267 |
| Evaluating the blood-brain barrier bioavailability and in vivo efficacy potential of a novel TAK1 inhibitor targeting chronic pain - project summary / abstract chronic pain is a prevalent health concern, affecting up to 100 million people and carrying an economic burden up to $560 billion annually i | Drug Use and Addiction Research Programs | September 8, 2021 | $480,955 |
Questions people ask
How much federal grant money does Eydis Bio, Inc. get?
$5.9 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Eydis Bio, Inc. the most?
The Department of Health and Human Services, with $5.9 million in 5 awards.
What is Eydis Bio, Inc.'s largest federal grant?
$2.6 million under Cardiovascular Diseases Research, with its first action in the period on July 10, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Eydis Bio, Inc.?
Its largest are Cardiovascular Diseases Research, Arthritis, Musculoskeletal and Skin Diseases Research and Aging Research.
Other grant recipients in Durham
- Duke University
- Family Health International
- North Carolina Central University
- Housing Authority of the City of Durham
- Rho Federal Systems Division Inc
- City of Durham
- Families & Communities Rising, Inc.
- Lincoln Community Health Center Incorporated
Largest federal grant recipients in North Carolina · Federal grants in North Carolina